TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating ...
We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...
Insider buying surged in February. Warren Buffett continues to build a stake in a media stock, and IPOs tempted some insiders ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
with Sionna Therapeutics and Odyssey Therapeutics launching bids for IPOs following the steps of Maze Therapeutics and Metsera. As the federal reserve steps further into the easing cycle in 2025 ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback